Medical significance of peroxisome proliferator-activated receptors

被引:460
|
作者
Vamecq, J
Latruffe, N
机构
[1] CHU Lille, INSERM, Neuropaediat Dept Prof Jean Pierre Nuyts, F-59037 Lille, France
[2] Univ Burgundy, Fac Sci Gabriel, Lab Mol & Cell Biol, Dijon, France
来源
LANCET | 1999年 / 354卷 / 9173期
关键词
D O I
10.1016/S0140-6736(98)10364-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peroxisome proliferator-activated receptors (PPAR) were discovered in 1990, ending 25 years of uncertainty about the molecular mechanisms of peroxisome proliferation. Subsequently, PPARs have improved our understanding of adipocyte differentiation. But there is more to PPARs than solving a puzzle about an organelle (the peroxisome) long considered an oddity, and their medical significance goes beyond obesity too. Enhanced PPAR type a: expression protects against cardiovascular disorders though the role of enhanced PPAR gamma expression seems less favourable. PPAR mechanisms, mainly via induction of more differentiated cell phenotypes, protect against some cancers. The differentiation of many cell types (hepatocyte, fibroblast, adipocyte, keratinocyte, myocyte, and monocyte/macrophege) involves PPARs, and these nuclear receptors are now attracting the attention of many medical specialties;and the pharmaceutical industry.
引用
收藏
页码:141 / 148
页数:8
相关论文
共 50 条
  • [1] Proliferating peroxisome proliferator-activated receptors
    不详
    [J]. DIABETES OBESITY & METABOLISM, 2000, 2 (05): : 332 - 333
  • [2] Peroxisome proliferator-activated receptors and inflammation
    Moraes, Leonardo A.
    Piqueras, Laura
    Bishop-Bailey, David
    [J]. PHARMACOLOGY & THERAPEUTICS, 2006, 110 (03) : 371 - 385
  • [3] Peroxisome proliferator-activated receptors and their functions
    Jiao, HL
    Ye, P
    Zhao, BL
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2001, 28 (04) : 478 - 481
  • [4] Peroxisome proliferator-activated receptors for hypertension
    Usuda, Daisuke
    Kanda, Tsugiyasu
    [J]. WORLD JOURNAL OF CARDIOLOGY, 2014, 6 (08): : 744 - 754
  • [5] Peroxisome proliferator-activated receptors.
    Ziouzenkova O.
    Perrey S.
    Marx N.
    Bacqueville D.
    Plutzky J.
    [J]. Current Atherosclerosis Reports, 2002, 4 (1) : 59 - 64
  • [6] Signalling by peroxisome proliferator-activated receptors
    Wahli, W
    Krey, G
    Devchand, P
    Keller, H
    Ijpenberg, A
    Jeannin, E
    Braissant, O
    Desvergne, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 : U79 - U79
  • [7] Regulation of peroxisome proliferator-activated receptors
    Sorensen, HN
    Treuter, E
    Gustafsson, JA
    [J]. VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 54, 1998, 54 : 121 - 166
  • [8] Peroxisome proliferator-activated receptors and angiogenesis
    Biscetti, F.
    Straface, G.
    Pitocco, D.
    Zaccardi, F.
    Ghirlanda, G.
    Flex, A.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2009, 19 (11) : 751 - 759
  • [9] Peroxisome Proliferator-Activated Receptors and Atherosclerosis
    Soskic, Sanja S.
    Dobutovic, Branislava D.
    Sudar, Emina M.
    Obradovic, Milan M.
    Nikolic, Dragana M.
    Zaric, Bozidarka L.
    Stojanovic, Srdan D.
    Stokic, Edita J.
    Mikhailidis, Dimitri P.
    Isenovic, Esma R.
    [J]. ANGIOLOGY, 2011, 62 (07) : 523 - 534
  • [10] Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and diseased
    Robinson, Emma
    Grieve, David J.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2009, 122 (03) : 246 - 263